Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada Strikes Deals With Lobsor And MediPharm

Lobsor Offers Value-Added Parkinson's Disease Treatment; MediPharm Adds Cannabis

Executive Summary

Stada's Britannia Pharmaceuticals has acquired Sweden's Lobsor and its Lecigon gel formulation which is already approved in the Nordics and combines levodopa, carbidopa and entacapone infused via a lightweight pump. Meanwhile, Stada has also formed an alliance with MediPharm Labs for medical cannabis.

You may also be interested in...



Stada Sales Increase By 18% In 2020 To Break Through €3bn Barrier

Stada enjoyed double-digit growth for revenues and profitability when adjusted for currency and one-time costs last year, as the privately-owned German firm championed its supply chain investments amid the coronavirus pandemic.

Stada Launches Medical Cannabis Portfolio

Stada has announced the launch of its medical cannabis portfolio under the brand CannabiStada in Germany. The company will be rolling out both flowers and whole extracts, primarily geared towards chronic pain patients for whom established medications, such as opioids, do not work.

Stada Launches Lecigon In Germany And Austria

Stada is kicking off the launch of its Lecigon gel in continental Europe by rolling out the value-added product – which combines levodopa, carbidopa and entacapone infused via a lightweight pump – in Germany and Austria.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel